OTC Denavir Advisory Cmte. Members Uncomfortable With Risk/Benefit Ratio
This article was originally published in The Tan Sheet
Executive Summary
A joint FDA advisory committee recommended against the Rx-to-OTC switch of SmithKline Beecham's Denavir in a narrow vote, with several members questioning whether the potential risks from broader access to the 1% penciclovir cream for cold sores may outweigh its benefits.
You may also be interested in...
NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse
NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse
NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
The presence of Nonprescription Drug Advisory Committee members as temporary voters on FDA's Drug Safety and Risk Management Advisory Committee brings expertise on OTC issues and a potential industry advocate to the Sept. 14 meeting on dextromethorphan abuse